- Home
- PHVS vs EYPT Comparison
PHVS vs EYPT Comparison
Compare PHVS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHVS | EYPT |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PHVS | EYPT |
|---|---|---|
| Price | $28.17 | $16.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $39.44 | $28.75 |
| AVG Volume (30 Days) | 205.6K | ★ 920.8K |
| Earning Date | 11-12-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.51 | $3.91 |
| 52 Week High | $29.80 | $19.11 |
Technical Indicators
Market Signals| Indicator | PHVS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 48.93 |
| Support Level | $24.51 | $14.50 |
| Resistance Level | $26.68 | $17.61 |
| Average True Range (ATR) | 1.58 | 1.06 |
| MACD | 0.20 | -0.24 |
| Stochastic Oscillator | 92.73 | 41.87 |
Price Performance
Historical ComparisonAbout PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.